<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00616031</url>
  </required_header>
  <id_info>
    <org_study_id>TRIC-TRIL-C0702</org_study_id>
    <secondary_id>CDR0000584254</secondary_id>
    <secondary_id>TRIC-C157</secondary_id>
    <nct_id>NCT00616031</nct_id>
  </id_info>
  <brief_title>Paclitaxel and Carboplatin With or Without Nitroglycerin in Treating Patients With Previously Untreated Stage III or Stage IV Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase II, Multinational and Multicenter, Randomized, Controlled Study of Paclitaxel and Carboplatin With vs Without Nitroglycerin in Patients With Untreated Advanced Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyoto University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Nitroglycerin may help carboplatin and paclitaxel work better by making tumor cells&#xD;
      more sensitive to the drugs.&#xD;
&#xD;
      PURPOSE: This phase II randomized trial is studying how well giving nitroglycerin together&#xD;
      with paclitaxel and carboplatin works and compares it to giving paclitaxel and carboplatin&#xD;
      alone in treating patients with previously untreated stage III or stage IV non-small cell&#xD;
      lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To evaluate tumor response rate and safety of nitroglycerin as a potentiator of&#xD;
           anticancer combination therapy comprising paclitaxel and carboplatin in patients with&#xD;
           previously untreated stage IIIB or IV non-small cell lung cancer.&#xD;
&#xD;
      OUTLINE: This is a multicenter, randomized, controlled study. Patients are randomized to 1 of&#xD;
      2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive nitroglycerin, paclitaxel, and carboplatin.&#xD;
&#xD;
        -  Arm II: Patients receive paclitaxel and carboplatin. In both arms, treatment continues&#xD;
           for 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2008</start_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor response rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event and its severity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the plasma concentration of VEGF between before and after the three-day administration of nitroglycerin prior to the start of the administration of anticancer drugs in the first course of the treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the number of endothelial progenitor cells in blood between before and after the three-day administration of nitroglycerin prior to the start of the administration of anticancer drugs in the first course of the treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood concentration of paclitaxel and carboplatin immediately and two hours after the administration of the anticancer drug (paclitaxel) in the first course of treatment</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nitroglycerin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed non-small cell lung cancer&#xD;
&#xD;
               -  Stage IIIB or IV disease that cannot be treated by radical irradiation&#xD;
&#xD;
          -  Tumor lesions must be objectively evaluated according to WHO criteria (maximum&#xD;
             diameter is no shorter than twice the slice width and no shorter than 10 mm) by CT&#xD;
             scan&#xD;
&#xD;
          -  No brain metastasis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  Neutrophil count &gt; 2,000/μL&#xD;
&#xD;
          -  Hemoglobin &gt; 10.0 g/dL&#xD;
&#xD;
          -  Platelet count &gt; 100,000/μL&#xD;
&#xD;
          -  Serum bilirubin &lt; 2.0 mg/dL&#xD;
&#xD;
          -  ALT and AST &lt; 100 IU/L&#xD;
&#xD;
          -  Serum creatinine &lt; 2.0 mg/dL&#xD;
&#xD;
          -  PaO_2 ≥ 70 mm Hg&#xD;
&#xD;
          -  No cardiac problems, including any of the following:&#xD;
&#xD;
               -  Poorly controlled hypertension&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  Congestive heart failure&#xD;
&#xD;
               -  Myocardial infarction within the past year&#xD;
&#xD;
               -  Ventricular arrhythmia that requires treatment except single, well-controlled&#xD;
                  isolated ventricular extrasystole&#xD;
&#xD;
          -  No chronic active hepatitis or cirrhosis requiring treatment except hepatitis virus&#xD;
             carriers who do not need treatment&#xD;
&#xD;
          -  No comorbidity of interstitial pneumonia and pulmonary fibrosis requiring treatment&#xD;
&#xD;
          -  No other cancer requiring treatment except a malignant tumor curatively resected with&#xD;
             no recurrence&#xD;
&#xD;
          -  No severe psychiatric disorders including schizophrenia or dementia&#xD;
&#xD;
          -  Cardiothoracic ratio &lt; 60% by chest x-ray&#xD;
&#xD;
          -  No history of severe drug allergy or allergy to polyoxyethylene castor oil (in some&#xD;
             anesthetic drugs or muscle relaxants) or polysorbate 80&#xD;
&#xD;
          -  Patients in whom nitroglycerin preparations are contraindicated are not eligible,&#xD;
             including any of the following:&#xD;
&#xD;
               -  Severe hypotension (e.g., systolic blood pressure ≤ 80 mm Hg)&#xD;
&#xD;
               -  Angle-closure glaucoma&#xD;
&#xD;
               -  History of hypersensitivity to nitrate/nitrite ester drugs&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior chemotherapy or radiotherapy&#xD;
&#xD;
               -  Pleurodesis is not considered chemotherapy&#xD;
&#xD;
          -  At least 1 week since prior and no other concurrent nitric oxide donors (e.g.,&#xD;
             nitroglycerin)&#xD;
&#xD;
          -  At least 1 week since prior and no concurrent calcium antagonists&#xD;
&#xD;
          -  At least 1 week since prior and no concurrent drugs for erectile dysfunction that&#xD;
             inhibit phosphodiesterase 5 (e.g., sildenafil citrate or vardenafil hydrochloride&#xD;
             hydrate)&#xD;
&#xD;
          -  More than 24 hours since prior and no concurrent administration of the following:&#xD;
&#xD;
               -  Antifungal azoles, including ketoconazole, miconazole, or itraconazole&#xD;
&#xD;
               -  Macrolides, including erythromycin or clarithromycin&#xD;
&#xD;
               -  Cyclosporines&#xD;
&#xD;
               -  Benzodiazepines, including diazepam, triazolam, or midazolam&#xD;
&#xD;
               -  Vitamin A&#xD;
&#xD;
               -  Steroid hormones, including ethinylestradiol&#xD;
&#xD;
          -  No concurrent participation in another clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hiroyasu Yasuda, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Tohoku University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Akiko Takeuchi</last_name>
    <affiliation>Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kyoto University Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiroyasu Yasuda, MD, PhD</last_name>
      <phone>81-75-751-4770</phone>
      <email>yasuda@kuhp.kyoto-u.ac.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>February 14, 2008</study_first_submitted>
  <study_first_submitted_qc>February 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2008</study_first_posted>
  <last_update_submitted>August 9, 2013</last_update_submitted>
  <last_update_submitted_qc>August 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2013</last_update_posted>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Nitroglycerin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

